Immix Biopharma Inc

NASDAQ IMMX

Download Data

Immix Biopharma Inc Current Liabilities to Total Liabilities Ratio 1 year YoY Change (%) for the year ending December 31, 2023: 37.30%

Immix Biopharma Inc Current Liabilities to Total Liabilities Ratio 1 year YoY Change (%) is 37.30% for the year ending December 31, 2023, a 237.30% change year over year. The current liabilities to total liabilities ratio measures the proportion of a company's current liabilities in relation to its total liabilities. It is calculated by dividing current liabilities by total liabilities. This ratio provides insights into the percentage of a company's total liabilities that are classified as current liabilities. It helps evaluate the company's overall liability structure and the importance of short-term obligations in relation to total liabilities. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Immix Biopharma Inc Current Liabilities to Total Liabilities Ratio for the year ending December 31, 2022 was 0.73, a -27.17% change year over year.
  • Immix Biopharma Inc Current Liabilities to Total Liabilities Ratio for the year ending December 31, 2021 was 1.00, a 0.00% change year over year.
  • Immix Biopharma Inc Current Liabilities to Total Liabilities Ratio for the year ending December 31, 2020 was 1.00, a 0.00% change year over year.
  • Immix Biopharma Inc Current Liabilities to Total Liabilities Ratio for the year ending December 31, 2019 was 1.00.
NASDAQ: IMMX

Immix Biopharma Inc

CEO Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date Dec. 16, 2021
Location United States
Headquarters 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Similar companies

HEPA

Hepion Pharmaceuticals Inc

NA

NA

AVRO

AVROBIO Inc

NA

NA

FRLN

Freeline Therapeutics Holdings Plc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email